Annual EBITDA
-$130.39 M
+$140.51 M+51.87%
31 December 2023
Summary:
Inovio Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$130.39 million, with the most recent change of +$140.51 million (+51.87%) on 31 December 2023. During the last 3 years, it has risen by +$19.17 million (+12.82%). INO annual EBITDA is now -2692.76% below its all-time high of -$4.67 million, reached on 01 March 2001.INO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$24.40 M
+$7.01 M+22.32%
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$24.40 million, with the most recent change of +$7.01 million (+22.32%) on 30 September 2024. Over the past year, it has increased by +$8.18 million (+25.12%). INO quarterly EBITDA is now -202.66% below its all-time high of $23.77 million, reached on 30 September 2020.INO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$109.89 M
+$8.18 M+6.93%
30 September 2024
Summary:
Inovio Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$109.89 million, with the most recent change of +$8.18 million (+6.93%) on 30 September 2024. Over the past year, it has increased by +$48.76 million (+30.73%). INO TTM EBITDA is now -6860.57% below its all-time high of -$1.58 million, reached on 31 March 1999.INO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +51.9% | +25.1% | +30.7% |
| 3 y3 years | +12.8% | +58.3% | +47.9% |
| 5 y5 years | -45.2% | -22.3% | -4.2% |
INO EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +56.0% | at high | +77.2% | at high | +68.2% |
| 5 y | 5 years | -45.2% | +56.0% | -202.7% | +80.4% | -4.2% | +68.2% |
| alltime | all time | -2692.8% | +56.0% | -202.7% | +80.4% | -6860.6% | +68.2% |
Inovio Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$24.40 M(-22.3%) | -$109.89 M(-6.9%) |
| June 2024 | - | -$31.41 M(+6.4%) | -$118.07 M(-2.2%) |
| Mar 2024 | - | -$29.53 M(+20.3%) | -$120.74 M(-7.4%) |
| Dec 2023 | -$130.39 M(-51.9%) | -$24.55 M(-24.7%) | -$130.39 M(-17.8%) |
| Sept 2023 | - | -$32.58 M(-4.4%) | -$158.65 M(-2.2%) |
| June 2023 | - | -$34.08 M(-13.0%) | -$162.17 M(-31.0%) |
| Mar 2023 | - | -$39.18 M(-25.8%) | -$234.87 M(-13.3%) |
| Dec 2022 | -$270.90 M(-8.7%) | -$52.80 M(+46.2%) | -$270.90 M(-16.2%) |
| Sept 2022 | - | -$36.11 M(-66.2%) | -$323.19 M(-6.5%) |
| June 2022 | - | -$106.77 M(+42.0%) | -$345.62 M(+8.2%) |
| Mar 2022 | - | -$75.22 M(-28.4%) | -$319.40 M(+7.7%) |
| Dec 2021 | -$296.56 M(+98.3%) | -$105.09 M(+79.5%) | -$296.56 M(+40.6%) |
| Sept 2021 | - | -$58.54 M(-27.3%) | -$210.92 M(+64.0%) |
| June 2021 | - | -$80.55 M(+53.8%) | -$128.62 M(-25.6%) |
| Mar 2021 | - | -$52.38 M(+169.3%) | -$172.83 M(+15.6%) |
| Dec 2020 | -$149.56 M(+39.3%) | -$19.45 M(-181.8%) | -$149.56 M(-8.6%) |
| Sept 2020 | - | $23.77 M(-119.1%) | -$163.70 M(-21.1%) |
| June 2020 | - | -$124.76 M(+328.5%) | -$207.43 M(+90.4%) |
| Mar 2020 | - | -$29.11 M(-13.3%) | -$108.96 M(+1.5%) |
| Dec 2019 | -$107.34 M(+19.5%) | -$33.60 M(+68.3%) | -$107.34 M(+1.8%) |
| Sept 2019 | - | -$19.96 M(-24.1%) | -$105.46 M(-3.5%) |
| June 2019 | - | -$26.29 M(-4.4%) | -$109.33 M(+23.6%) |
| Mar 2019 | - | -$27.50 M(-13.3%) | -$88.42 M(-4.3%) |
| Dec 2018 | -$89.80 M(+6.0%) | -$31.72 M(+33.1%) | -$92.37 M(+5.4%) |
| Sept 2018 | - | -$23.82 M(+342.5%) | -$87.60 M(-4.6%) |
| June 2018 | - | -$5.38 M(-82.9%) | -$91.80 M(-3.5%) |
| Mar 2018 | - | -$31.44 M(+16.7%) | -$95.15 M(+12.3%) |
| Dec 2017 | -$84.71 M(+14.2%) | -$26.95 M(-3.8%) | -$84.71 M(+6.8%) |
| Sept 2017 | - | -$28.02 M(+220.9%) | -$79.30 M(+12.3%) |
| June 2017 | - | -$8.73 M(-58.4%) | -$70.60 M(-12.1%) |
| Mar 2017 | - | -$21.01 M(-2.5%) | -$80.30 M(+8.3%) |
| Dec 2016 | -$74.15 M(+122.2%) | -$21.54 M(+11.5%) | -$74.15 M(+11.3%) |
| Sept 2016 | - | -$19.32 M(+4.8%) | -$66.61 M(+54.7%) |
| June 2016 | - | -$18.44 M(+24.1%) | -$43.06 M(+6.9%) |
| Mar 2016 | - | -$14.85 M(+6.1%) | -$40.29 M(+20.7%) |
| Dec 2015 | -$33.37 M(-12.0%) | -$14.00 M(-431.1%) | -$33.37 M(+11.4%) |
| Sept 2015 | - | $4.23 M(-127.0%) | -$29.95 M(-28.8%) |
| June 2015 | - | -$15.66 M(+97.5%) | -$42.09 M(+16.2%) |
| Mar 2015 | - | -$7.93 M(-25.1%) | -$36.21 M(-4.5%) |
| Dec 2014 | -$37.93 M(+95.0%) | -$10.58 M(+33.8%) | -$37.93 M(+6.2%) |
| Sept 2014 | - | -$7.91 M(-19.2%) | -$35.70 M(+34.5%) |
| June 2014 | - | -$9.79 M(+1.5%) | -$26.54 M(+15.7%) |
| Mar 2014 | - | -$9.64 M(+15.3%) | -$22.94 M(+18.0%) |
| Dec 2013 | -$19.45 M(-14.1%) | -$8.36 M(-769.6%) | -$19.45 M(+15.7%) |
| Sept 2013 | - | $1.25 M(-120.2%) | -$16.81 M(-31.0%) |
| June 2013 | - | -$6.19 M(+0.6%) | -$24.35 M(-0.4%) |
| Mar 2013 | - | -$6.15 M(+7.3%) | -$24.46 M(+8.0%) |
| Dec 2012 | -$22.65 M(+12.1%) | -$5.73 M(-9.0%) | -$22.65 M(+2.0%) |
| Sept 2012 | - | -$6.29 M(+0.0%) | -$22.20 M(+0.5%) |
| June 2012 | - | -$6.29 M(+44.9%) | -$22.08 M(+8.1%) |
| Mar 2012 | - | -$4.34 M(-17.7%) | -$20.42 M(+1.0%) |
| Dec 2011 | -$20.21 M | -$5.28 M(-14.5%) | -$20.21 M(+2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$6.17 M(+33.2%) | -$19.69 M(+12.2%) |
| June 2011 | - | -$4.63 M(+12.1%) | -$17.55 M(+1.1%) |
| Mar 2011 | - | -$4.13 M(-13.1%) | -$17.36 M(+1.4%) |
| Dec 2010 | -$17.11 M(+39.3%) | -$4.75 M(+18.0%) | -$17.11 M(+9.6%) |
| Sept 2010 | - | -$4.03 M(-9.4%) | -$15.61 M(+6.7%) |
| June 2010 | - | -$4.45 M(+14.4%) | -$14.63 M(+14.0%) |
| Mar 2010 | - | -$3.88 M(+19.4%) | -$12.83 M(+4.5%) |
| Dec 2009 | -$12.28 M(-3.0%) | -$3.25 M(+6.9%) | -$12.28 M(+0.2%) |
| Sept 2009 | - | -$3.04 M(+14.9%) | -$12.25 M(+4.6%) |
| June 2009 | - | -$2.65 M(-20.5%) | -$11.71 M(-9.2%) |
| Mar 2009 | - | -$3.33 M(+3.3%) | -$12.89 M(+1.8%) |
| Dec 2008 | -$12.67 M(-15.2%) | -$3.23 M(+29.0%) | -$12.67 M(+14.7%) |
| Sept 2008 | - | -$2.50 M(-34.7%) | -$11.04 M(-16.9%) |
| June 2008 | - | -$3.83 M(+23.3%) | -$13.29 M(-4.9%) |
| Mar 2008 | - | -$3.11 M(+93.6%) | -$13.98 M(-6.5%) |
| Dec 2007 | -$14.94 M(+20.2%) | -$1.60 M(-66.2%) | -$14.94 M(-12.0%) |
| Sept 2007 | - | -$4.74 M(+4.9%) | -$16.97 M(+9.7%) |
| June 2007 | - | -$4.52 M(+11.0%) | -$15.47 M(+11.0%) |
| Mar 2007 | - | -$4.07 M(+12.1%) | -$13.94 M(+12.1%) |
| Dec 2006 | -$12.43 M(+9.3%) | -$3.63 M(+12.0%) | -$12.43 M(+6.2%) |
| Sept 2006 | - | -$3.24 M(+8.5%) | -$11.70 M(+3.9%) |
| June 2006 | - | -$2.99 M(+16.6%) | -$11.26 M(+10.0%) |
| Mar 2006 | - | -$2.56 M(-11.7%) | -$10.24 M(-10.0%) |
| Dec 2005 | -$11.38 M(+4.0%) | -$2.90 M(+3.5%) | -$11.38 M(-6.8%) |
| Sept 2005 | - | -$2.80 M(+42.4%) | -$12.21 M(-4.6%) |
| June 2005 | - | -$1.97 M(-46.7%) | -$12.80 M(-2.7%) |
| Mar 2005 | - | -$3.70 M(-1.0%) | -$13.15 M(+20.3%) |
| Dec 2004 | -$10.94 M(+80.8%) | -$3.73 M(+10.0%) | -$10.94 M(+23.5%) |
| Sept 2004 | - | -$3.40 M(+46.0%) | -$8.86 M(+26.3%) |
| June 2004 | - | -$2.33 M(+56.8%) | -$7.01 M(+18.0%) |
| Mar 2004 | - | -$1.48 M(-10.4%) | -$5.95 M(-2.0%) |
| Dec 2003 | -$6.05 M(+14.5%) | -$1.65 M(+6.6%) | -$6.07 M(+6.9%) |
| Sept 2003 | - | -$1.55 M(+23.4%) | -$5.68 M(+4.5%) |
| June 2003 | - | -$1.26 M(-21.5%) | -$5.43 M(-2.0%) |
| Mar 2003 | - | -$1.60 M(+26.7%) | -$5.54 M(+5.0%) |
| Dec 2002 | -$5.28 M(-0.5%) | -$1.26 M(-3.3%) | -$5.28 M(+31.5%) |
| Sept 2002 | - | -$1.31 M(-4.4%) | -$4.01 M(-5.4%) |
| June 2002 | - | -$1.37 M(+2.1%) | -$4.24 M(-22.0%) |
| Mar 2002 | - | -$1.34 M(-12.9%) | -$5.44 M(+10.4%) |
| Dec 2001 | -$5.31 M(+13.7%) | - | - |
| Sept 2001 | - | -$1.54 M(-40.1%) | -$4.93 M(-6.8%) |
| June 2001 | - | -$2.57 M(-297.9%) | -$5.29 M(+13.3%) |
| Mar 2001 | - | $1.30 M(-161.1%) | -$4.67 M(-44.0%) |
| Mar 2001 | -$4.67 M(-47.9%) | - | - |
| Dec 2000 | - | -$2.12 M(+11.8%) | -$8.33 M(+5.3%) |
| Sept 2000 | - | -$1.90 M(-2.5%) | -$7.91 M(-0.0%) |
| June 2000 | - | -$1.95 M(-17.8%) | -$7.91 M(-10.8%) |
| Mar 2000 | -$8.97 M(+38.4%) | -$2.37 M(+39.3%) | -$8.87 M(+78.1%) |
| Dec 1999 | - | -$1.70 M(-10.5%) | -$4.98 M(-21.9%) |
| Sept 1999 | - | -$1.90 M(-34.5%) | -$6.38 M(+42.4%) |
| June 1999 | - | -$2.90 M(-290.6%) | -$4.48 M(+183.7%) |
| Mar 1999 | -$6.48 M | $1.52 M(-149.1%) | -$1.58 M(-49.1%) |
| Dec 1998 | - | -$3.10 M | -$3.10 M |
FAQ
- What is Inovio Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual EBITDA year-on-year change?
- What is Inovio Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Inovio Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals TTM EBITDA year-on-year change?
What is Inovio Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of INO is -$130.39 M
What is the all time high annual EBITDA for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is -$4.67 M
What is Inovio Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, INO annual earnings before interest, taxes, depreciation & amortization has changed by +$140.51 M (+51.87%)
What is Inovio Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of INO is -$24.40 M
What is the all time high quarterly EBITDA for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $23.77 M
What is Inovio Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, INO quarterly earnings before interest, taxes, depreciation & amortization has changed by +$8.18 M (+25.12%)
What is Inovio Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of INO is -$109.89 M
What is the all time high TTM EBITDA for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.58 M
What is Inovio Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, INO TTM earnings before interest, taxes, depreciation & amortization has changed by +$48.76 M (+30.73%)